These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148 [Abstract] [Full Text] [Related]
4. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Forbes JF. Semin Oncol; 2006 Apr 10; 33(2 Suppl 7):S2-7. PubMed ID: 16730270 [Abstract] [Full Text] [Related]
5. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R. Clin Cancer Res; 2005 Aug 15; 11(16):5671-7. PubMed ID: 16115902 [Abstract] [Full Text] [Related]
7. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE. Breast Cancer Res Treat; 2006 Oct 15; 99(3):295-300. PubMed ID: 16541302 [Abstract] [Full Text] [Related]
11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M. J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550 [Abstract] [Full Text] [Related]
14. Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. Koeberle D, Thuerlimann B. Expert Rev Anticancer Ther; 2006 Jan 01; 6(1):5-10. PubMed ID: 16375638 [Abstract] [Full Text] [Related]
15. Understanding the BIG results: Insights from the BIG 1-98 trial analyses. Wardley AM. Adv Ther; 2008 Dec 01; 25(12):1257-75. PubMed ID: 19096768 [Abstract] [Full Text] [Related]
16. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. J Clin Oncol; 2007 Sep 01; 25(25):3846-52. PubMed ID: 17679725 [Abstract] [Full Text] [Related]